FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer

Drug

Anktiva (nogapendekin alfa inbakicept-pmln) · IL-15 receptor alpha fusion protein

Condition

Genitourinary